Amedisys: Hold Rating Amid Mixed Financial Signals and Uncertainty Post-Merger Announcement
Amedisys | 10-Q: Q1 2025 Earnings Report
Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Siemens Healthineers AG (OtherSEMHF) and Penumbra (PEN)
William Blair Maintains Amedisys(AMED.US) With Hold Rating
William Blair Sticks to Its Hold Rating for Amedisys (AMED)
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
AMEDISYS Earnings Results: $AMED Reports Quarterly Earnings
Amedisys Non-GAAP EPS of $1.25 Beats by $0.14, Revenue of $594.8M Misses by $1.69M
Amedisys Q1 Profit Increases, Beats Estimates
Amedisys Extends Credit Facility Amid Merger Talks
Express News | Amedisys Q1 Net Income USD 61 Million
Express News | Amedisys Q1 Net Service Revenue USD 594.8 Million
Express News | Amedisys Q1 Adjusted Ebitda USD 68.8 Million Vs. IBES Estimate USD 60.8 Million
Express News | Amedisys Q1 Adjusted Net Income USD 41.6 Million Vs. IBES Estimate USD 36.4 Million
Amedisys 1Q Adj EPS $1.25 >AMED
Amedisys 1Q EPS $1.84 >AMED
Amedisys | 8-K: AMEDISYS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
RBC Capital Maintains Amedisys(AMED.US) With Buy Rating, Maintains Target Price $100
RBC Capital Reiterates Outperform on Amedisys, Maintains $100 Price Target
Cantor Fitzgerald Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101